Completed PHASE1 INTERVENTIONAL NCT00258271

Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia

A Phase I Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Refractory or Relapsed Leukemias

Sponsor: University of Rochester

Conditions Leukemia

Interventions cladribine cytarabine filgrastim imatinib mesylate

Updated 5 times since 2017 Last updated: Oct 14, 2013 Started: Mar 31, 2005 Primary completion: Oct 31, 2006 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Leukemia, this trial is completed. The trial is conducted by University of Rochester and has accumulated 5 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Rochester

Data source: University of Rochester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States